Categories: News Reports

Temasek Holdings Invests in HCG Enterprises Ltd.

Bangalore, Karnataka, India, Monday, March 11, 2013 — (Business Wire India) — HealthCare Global Enterprises Limited, (HCG), the Specialist in Cancer Care, today announced that Temasek Holdings, a Singapore based investment company, has become a shareholder in the company.

Temasek joins existing investors, Premji Invest, an investment entity owned by Mr. Azim Premji, and Milestone Religare in a primary equity issuance by the Company. Evolvence India Life Sciences Fund, which has been an investor in HCG since 2007, will be exiting their investment to Temasek in the Company.

“We are happy to bring on board an equity partner of the stature of Temasek as we begin the next phase of growth. Temasek’s global perspective and long term interest in healthcare makes them a valuable partner. We also welcome Dr. Jennifer Lee to our board and look forward to benefiting from her vast experiences in health management and policy”, said Dr. B.S. Ajaikumar, Chairman and CEO of HCG Enterprises Ltd.

“We are pleased to have the opportunity to invest in HCG, who have redefined cancer care in India,” said Rohit Sipahimalani, Head- India, Temasek Holdings.

About HCG Enterprises Ltd:

Health Care Global Enterprises Ltd, (HCG), The Specialist in Cancer Care, headquartered in Bangalore with over 26 centers is Asia’s largest cancer care network. HCG has defined the future of cancer care in India by designing, building and managing cancer care centers with a committed vision. HCG focuses on cancer care treatment, imaging and laboratory services, clinical trials and research services. The vision of HCG is to make high quality cancer care accessible by adopting global innovations to all segments of the society.

For more information on HCG, please visit www.hcgoncology.com < http://www.hcgoncology.com/ >

About Temasek:

Incorporated in 1974, Temasek is an investment company based in Singapore, with 11 affiliates and offices in Asia and Latin America. Temasek owns a S$198 billion (US$157 billion) portfolio as at 31 March 2012, mainly in Singapore and Asia.

Temasek’s investment themes centre on:

— Transforming Economies

— Growing Middle Income Populations

— Deepening Comparative Advantages

— Emerging Champions

Temasek’s portfolio covers a broad spectrum of industries: energy & resources; financial services; transportation, logistics and industrials; telecommunications, media & technology; life sciences and consumer & real estate.

Total shareholder return since inception in 1974 has been a healthy 17% compounded annually. The company has a corporate credit rating of AAA/Aaa by rating agencies Standard & Poor’s and Moody’s respectively.

For more information on Temasek, please visit www.temasek.com.sg < http://www.temasek.com.sg/ >

The Pharma Times News Bureau

Recent Posts

Doctors warn diabetes patients about risk of smoking

People who smoke are also at much higher risk of developing diabetes compared to non-smokers…

20 hours ago

CPHI & PMEC India Expo: Encouraging affordable solutions in India’s march towards a $130 Billion Pharma Market by 2030

17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…

20 hours ago

Sringeri Sharada Equitas Hospital Revolutionizing Cancer Care with the Launch of Low-cost, High Quality Radiation Therapy

The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…

2 days ago

From Pain to Relief: How endoscopic spine surgery enhances patient outcomes

By DR UMESH SRIKANTHA, Senior Consultant - Neurosurgery, Head of Spine Services, Aster RV Hospital …

3 days ago

Henkel India Unveils Dedicated Researchers’ World Lab in India

Pune, November 11, 2024: Henkel Adhesives Technologies India Private Limited (Henkel India) announces the opening…

3 days ago